Theralase Technologies (CVE:TLT) Trading Down 3.6% – Should You Sell?

Theralase Technologies Inc. (CVE:TLT)’s stock price traded down 3.6% during mid-day trading on Friday . The stock traded as low as C$0.27 and last traded at C$0.27. 197,449 shares changed hands during mid-day trading, an increase of 3% from the average session volume of 192,614 shares. The stock had previously closed at C$0.28.

Theralase Technologies Trading Down 3.6%

The stock has a market cap of C$71.53 million, a P/E ratio of -15.00 and a beta of -0.29. The company has a current ratio of 0.83, a quick ratio of 3.40 and a debt-to-equity ratio of 29.26. The company has a 50-day moving average price of C$0.28 and a two-hundred day moving average price of C$0.22.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.